Boston faces consequence of Guidant buy with second recall in two months
This article was originally published in Clinica
Shares in Boston Scientific are wallowing at a near four-year low after the company this week recalled over 20,000 heart devices manufactured by Guidant due to a faulty component.
You may also be interested in...
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.